meta
|
evidence
oncology
Living systematic review and meta-analysis
malignant mesothelioma (mMS) - 1st line (L1)
1
immune chekpoint inhibitors
Immune checkpoint association
nivolumab plus ipilimumab
no study with result for this clinical condition